NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.10 (+3.65%)

Company Metrics

  • P/E 0
  • P/S 4.51
  • P/B 27.9
  • EPS -5.95
  • Cash ROIC 921.20%
  • Cash Ratio 0.51
  • Dividend 0 / N/A %
  • Avg. Vol. 33,281.00
  • Shares 2.78M
  • Market Cap. 26.00M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Latest Analyst Reports On NovaBay Pharmaceuticals, Inc.
Risers & Fallers - May 27, 2016
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market.
NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 05/12/16; Press Release. NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results.
Zacks: NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Receives Consensus ...
The Vista Voice - Apr 16, 2016
NovaBay Pharmaceuticals logo NovaBay Pharmaceuticals, Inc. (NYSE:NBY) has been given a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports.
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Receives Average Rating of "Hold ...
NewsWay 21 - May 9, 2016
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) has been assigned a consensus broker rating score of 0.00 () from the zero analysts that provide coverage for the company, Zacks Investment Research reports.
NovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors - Business Wire (press release)
NovaBay Pharmaceuticals, Inc. (NBY) Broker Price Targets For The Coming Week - Share Trading News
NovaBay Pharmaceuticals, Inc. (NBY) Falls in Pre-market Before Skyrocketing ...
Independent Reporter - Dec 21, 2015
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) fell considerably in pre-market trading this morning, before skyrocking after the market opened.
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Reports 2016 First ...
The Wall Street Transcript - May 12, 2016
EMERYVILLE, Calif. (May 12, 2016) - NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial ...
BRIEF-Novabay Pharmaceuticals appoints Todd Zavodnick to its board
Reuters - May 9, 2016
May 9 Novabay Pharmaceuticals Inc. * Novabay Pharmaceuticals appoints Todd Zavodnick to its board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780) ...
HC Stocks Reports: Atossa Genetics Inc (NASDAQ:ATOS), NovaBay Pharmaceuticals ...
share market updates (press release) - May 23, 2016
Shares of Atossa Genetics Inc (NASDAQ:ATOS) ended Friday session in red amid volatile trading. The shares closed down -0.007 points or -2.74% at $0.263 with 111,851.00 shares getting traded.
Biotechnology Unusual Volume: Cidara Therapeutics (NASDAQ:CDTX), NovaBay ... - Benchmark Monitor
Best Stocks: Denbury Resources Inc. (NYSE:DNR), NovaBay Pharmaceuticals, Inc ...
KC Register - May 23, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) traded 126753 shares and its share price increased 6.30% to close at $2.85.